These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11413920)

  • 1. [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
    Kellner H
    Z Gastroenterol; 2001 May; 39(5):443-5. PubMed ID: 11413920
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective COX-2 inhibitor. Stomach protection--but not always].
    MMW Fortschr Med; 2001 Jun; 143(25):60. PubMed ID: 11469005
    [No Abstract]   [Full Text] [Related]  

  • 4. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
    MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of the VIGOR study. Rofecoxib halves the complication rate].
    MMW Fortschr Med; 2001 Jun; 143(23):35. PubMed ID: 11460417
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
    Morović-Vergles J
    Reumatizam; 2003; 50(2):47-8. PubMed ID: 15098376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
    Infante R; Lahita RG
    Geriatrics; 2000 Mar; 55(3):30-2, 35-6, 39-40. PubMed ID: 10732003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
    MMW Fortschr Med; 2003 Aug; 145(31-32):56-7. PubMed ID: 14524083
    [No Abstract]   [Full Text] [Related]  

  • 15. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib for rheumatoid arthritis.
    Megeff CE; Strayer SM
    J Fam Pract; 2000 Feb; 49(2):108-9. PubMed ID: 10718683
    [No Abstract]   [Full Text] [Related]  

  • 19. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.